Pharma Q2 Preview : Cipla to see steady qtr ; higher profit growth for DRL
Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three (...)
Site référencé: The Economic Times
The Economic Times
RBI to slowly shift towards regulations based on outcomes
20/08/2025
Three out of six members on RBI's monetary policy committee acknowledged space for August rate cut : MPC Minutes
20/08/2025
Big investors ditch tech ahead of expected September stocks slump
20/08/2025
China considering yuan-backed stablecoins to boost global currency usage, sources say
20/08/2025
Gold drops Rs 400 to Rs 1,00,020/10 g, silver plunges Rs 1,500
20/08/2025
Turnaround Story : 9 stocks shift from loss to profit in June '25 quarter YoY
20/08/2025